Searched for
PATENTED CANCER DRUGS
Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...- Cancer drug price cuts leave costly brands untouchedPrices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices ...
- Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruptionDr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...
- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Germany's Bayer to invest $2.2 billion in US pharma siteBayer has announced a significant investment of $2.2 billion to establish a new pharmaceutical site in New Albany, Ohio. This project follo...
- ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...
- 14-year-old Indian-origin student develops handheld AI pesticide detector, named America’s Top Young ScientistA 14-year-old Indian-origin student from Georgia has gained recognition for developing PestiSCAND, a handheld device that uses artificial i...
- Kerala HC says exorbitant drug prices can trigger government intervention in patented medicinesThe Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...
- Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in IndiaNovartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, d...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...
- Policy lethargy must end to hold drug prices downA superior option is for the government to impose price controls on expensive drugs, whether imported or produced domestically.
- DIPP examining proposal to issue CL for 3 anti-cancer drugs"The DIPP is expected to ask for some more details from different ministries, including the Health Ministry," the source added.
- Cipla has not infringed F Hoffman La-Roche's patent cancer drug: High CourtThe Delhi HC held that Indian pharma major Cipla has not infringed upon the patent right of Swiss drug co F Hoffman La-Roche on a cancer dr...
Load More
